TICKERNERD
Menu
MNKDMNKDHealthcare · Biotechnology

MNKD Stock Forecast: MannKind Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.75
−1.06% on the day

The 8 Wall Street analysts covering MannKind Corp. hold a median 12-month price target of $7.5 — +100.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
34 / 100
Median analyst target
$7.50
Analysts covering
8
Revenue$109.4M+42.9% y/y
Operating income−$835K
Net income−$19.0M
Free cash flow−$23.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.3%
1M
−2.3%
YTD
−33.9%
1Y
−30.8%
From 52W high
−39.6%
From 52W low
+64.5%
$2.28
$6.21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MNKD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MannKind Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
92
Value
84
Volatility
45
Size
43
Momentum
41
Accruals
35
Growth
33
Revisions
28
Issuance
15

Quality (92): The business earns solid, repeatable profits on what it owns.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MNKD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MNKD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26MNKDHigh $13.00Median $7.50Low $4.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $4.75Median $7.50High $13.00

The green dot is the last close — the median target sits +100.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
11 Sept 2026Cantor FitzgeraldReiteratesOverweight$8.00
6 Aug 2026Wells FargoMaintainsOverweight$14 → $13
30 July 2026Wells FargoMaintainsOverweight$11 → $14
7 May 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026HC Wainwright & Co.MaintainsBuy$8.00 → $10
7 May 2026MizuhoMaintainsOutperform—
7 May 2026MizuhoMaintainsOutperform$8.00 → $7.00
7 May 2026RBC CapitalMaintainsSector Perform$3.50 → $4.75
7 May 2026RBC CapitalMaintainsSector Perform—
7 May 2026Wells FargoMaintainsOverweight$8.00 → $10
7 May 2026Wells FargoMaintainsOverweight—
28 Apr 2026Wells FargoMaintainsOverweight—
13 Apr 2026MizuhoMaintainsOutperform—
5 Mar 2026WedbushMaintainsOutperform—
27 Feb 2026HC Wainwright & Co.MaintainsBuy—
27 Feb 2026RBC CapitalDowngradeSector Perform—
27 Feb 2026Wells FargoMaintainsOverweight—
25 Feb 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026HC Wainwright& Co.ReiteratesBuy—
26 Jan 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MNKD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MNKD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, MannKind Corp. returned −30.8% against +17.5% for the S&P 500, dividends included.

MNKD vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26MNKDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MNKD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−64.7%
Analysts raising
0
Analysts cutting
0
Fundamentals

MannKind Corp. (MNKD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
193.5×

Cheaper than 4% of US stocks

Price / sales
3.1×

Cheaper than 40% of US stocks

Price / book
−17.3×

Cheaper than 98% of US stocks

EV / EBITDA
78.2×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
42.9%

Higher than 84% of US stocks

Earnings growth (YoY)
42.9%

Higher than 72% of US stocks

Gross margin
73.0%

Higher than 85% of US stocks

Operating margin
−0.8%

Higher than 31% of US stocks

Net margin
−11.1%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−11.5%

Higher than 35% of US stocks

Return on assets
0.8%

Higher than 48% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MannKind Corp. (MNKD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MannKind Corp. has a market value of $1.2B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $393.6M. The latest quarter grew 42.9% year on year.

  • Net income over the same four quarters: −$43.6M, a −11.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.13.

  • Free cash flow in the twelve months to 30 June 2026: −$18.1M.

  • Shares outstanding: 309.9M.

  • Trailing P/E: 193.5×; forward P/E: 29.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MannKind Corp. employs 591 people — $666K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MNKD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MNKDMannKind Corp.$1.2B
34
SLBTSL Science Holding Ltd.$1.2B
0
ODTXOdyssey Therapeutics, Inc.$1.2B
0
ALMSAlumis, Inc.$1.2B
43
JBIOJade Biosciences, Inc.$1.1B
24
MGTXMeiragtx Holdings plc$1.2B
81
GLUEMonte Rosa Therapeutics, Inc.$1.2B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MannKind Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MNKD news & analysis

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

Benzinga · 9 Sept 2026negative

MannKind Corporation announced a licensing and collaboration deal with Rose Pharma for an inhaled, rapid-acting GLP-1 program. The company's shares were trading lower on Wednesday as traders reacted to this news.

Why it matters — MannKind watchers would follow this because the partnership expands MannKind's pipeline into inhaled GLP-1 weight-management territory, though the immediate market reaction was a decline in the share price.

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

GlobeNewsWire · 9 Sept 2026positive

MannKind and Rose Pharma have entered a licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 for weight management. The partnership combines Rose Pharma's investigational GLP-1 receptor agonist with MannKind's Technosphere inhalation technology, with MannKind receiving an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through a Phase 1b study.

Why it matters — MNKD watchers would care because this expands MannKind's Technosphere platform into the weight-management space and brings potential equity and royalty income through a new licensing partnership.

MannKind to Present at Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

MannKind Corp. announced it will present at upcoming investor conferences, according to a press release from the company's Danbury, Connecticut and Westlake Village, California offices.

Why it matters — MNKD watchers would want to know when and where company management is presenting, as these events offer potential visibility into the company's business strategy and updates.

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

Zacks Investment Research · 28 Aug 2026neutral

The FDA accepted United Therapeutics' New Drug Application for ralinepag, a treatment for pulmonary arterial hypertension (PAH), with a decision expected in 2027. The filing is supported by positive phase III trial data.

Why it matters — The acceptance could signal increased competition in the PAH treatment space, an area where MannKind Corp. has related interests.

MannKind: New Approvals Majorly Increase MannKind's Prospects

Seeking Alpha · 13 Aug 2026positive

MannKind continues to see modest growth from its three revenue streams, and two new FDA approvals are expected to significantly boost growth in two of its established products. The company's existing liquidity is projected to fund operations and launches for about 2.3 years.

Why it matters — MNKD watchers would care because the two new FDA approvals could materially accelerate growth in established products, reinforcing the company's growth outlook.

FAQ

Frequently asked questions about MNKD stock

What is the MNKD stock price forecast for 2026-2027?

The 8 Wall Street analysts covering MannKind Corp. have a median 12-month price target of $7.5, with estimates ranging from $4.75 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MNKD stock a buy right now?

Of the 8 analysts covering MannKind Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MannKind Corp. 34 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MNKD?

As at 12 Sept 2026, MannKind Corp. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).

Will MNKD stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +100.0% from the last close, and Ticker Nerd's factor model ranks MannKind Corp. 34 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MNKD stock forecast for 2030?

No analyst covering MannKind Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNKD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $13 over the next 12 months.

How has MNKD stock performed over the past year?

MannKind Corp. returned -30.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MannKind Corp. do?

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion.

What is the latest news on MNKD?

The most recent item we track (Benzinga, 9 Sept 2026): "Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule". MannKind Corporation announced a licensing and collaboration deal with Rose Pharma for an inhaled, rapid-acting GLP-1 program. The company's shares were trading lower on Wednesday as traders reacted to this news.

Company

About MannKind Corp.

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion. The company also markets Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension, extending its presence in specialty respiratory care. MannKind Corporation serves patients and healthcare providers across endocrine and lung disease markets, with products designed to address chronic conditions that require convenient, patient-centered treatment options. Headquartered in Danbury, Connecticut, MannKind Corporation operates as a focused healthcare business centered on innovative drug delivery and disease management solutions.

CEO Dr. Michael E. Castagna Pharm.D. · 591 employees · United States · https://mannkindcorp.com